# Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

> **NCT01390220** · PHASE3 · TERMINATED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 292 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** USL261
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01390220
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01390220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01390220, "Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01390220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*